In January J&J announced that vaccine efficacy reached 72% in the U.S., compared with just 57% in South Africa.
Khonamanjalo, i-J & J imemezele ngoLwesihlanu ukuthi ukusebenza ngokugoma kufinyelele kuma-72% e-U.S., Uma kuqhathaniswa no-57% kuphela eNingizimu Afrika.